Transpire Bio Announces Progress in Clinical Development with Initiation of a New Human Subject Study for Asthma and COPD Inhaled Drug Program
News WESTON, Fla., Jan. 13, 2024 (GLOBE NEWSWIRE) Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the commencement of a new human subject study for its inhalation therapy program targeting asthma and chronic obstructive pulmonary disease (COPD). This advancement builds on the promising results from a previous clinical […]
Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
News Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine WESTON, Fla., July 7, 2025 (GLOBE NEWSWIRE) — Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has announced a definitive agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment […]
